Kilani, RT1; Tamimi, Y1; Karmali, S1; Mackey, J2; Hanel, EG1; Wong, KK1; Moore, RB1
Author Information
1Department of Experimental Surgery and Division of Urology, University of Alberta and Department of Surgery, Cross Cancer Institute, Edmonton, Alberta 6G 1Z2, Canada
2Department of Oncology, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada
The financial support ‘in part’ was provided by the Alberta Heritage Foundation of Medical Research and the Alberta Cancer Board. Gemcitabine was gift from Eli Lilly, Inc, Indianapolis, IN.
Correspondence to RB Moore, Department of Surgery, University of Alberta, 2D2.17 Walter Mackenzie Health Sciences Center, Edmonton, Alberta T6G 2R7, Canada.
Tel: (+1) 780 492-6330; Fax: (+1) 780 492-4923;
E-mail: [email protected]
Received 20 March 2002 accepted 16 April 2002
